ROCHESTER, Minn. — Two Mayo Clinic patients whose prostate cancer had been considered inoperable are now cancer free thanks in part to an experimental drug therapy that was used in combination with standardized hormone treatment and radiation therapy. The men were participating in a clinical trial of an immunotherapeutic agent...
Latest News
Ann Arbor, Mich. – Over the last decade, research at Michigan Medicine has shown how exposure to toxins in the environment, such as pesticides and carcinogenic PCBs, affect the risk of developing and dying from amyotrophic lateral sclerosis. Now, investigators have developed an environmental risk score that assesses a person’s risk...
PARIS, France – In a groundbreaking endeavour set to span five years, the DREAMS consortium is paving the way for a novel approach to treating neuromuscular diseases. This transformative project merges the power of artificial intelligence, pluripotent stem cells, and cutting-edge pharmacological screening techniques to seek out therapeutic solutions for...
Iowa City, Iowa – Did smokers do better than non-smokers in a clinical trial for an experimental cancer treatment? That was the intriguing question that led University of Iowa researchers and their colleagues to develop a drinkable, carbon monoxide-infused foam that boosted the effectiveness of the therapy, known as autophagy...
New Cleveland Clinic research found that drugs originally designed to help treat Alzheimer’s disease may hold promise for glioblastoma, the most common and lethal type of primary brain tumor. The findings were published in Nature Cancer. A class of drugs called BACE1 inhibitors were once among the most anticipated candidates...
GUILFORD, Conn. & SHANGHAI, China – Drug Farm announced today the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application of DF-003, a first-in-class, oral, potent, highly selective alpha-kinase 1 (ALPK1) inhibitor for clinical evaluation in ROSAH syndrome patients. The trial will assess the safety,...
GUILFORD, Conn. — Drug Farm, a clinical-stage biopharmaceutical company announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) Designation for the company’s alpha-kinase 1 (ALPK1) inhibitor, DF-003, to treat patients with ROSAH (retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis and headache ) Syndrome. DF-003...
San Antonio, Texas – A drug effective in treating breast cancer shows new promise in addressing breast cancer with brain metastases or recurrent glioblastoma, as reported by results of a prospective window-of-opportunity trial at the University of Texas Health Science Center at San Antonio (UT Health San Antonio). The window...
New York, NY – A drug currently in clinical trials as a cancer therapy can also stimulate pancreatic beta cells to secrete insulin, revealing a previously unknown mechanism for insulin regulation in type 2 diabetes, according to a new study by Weill Cornell Medicine investigators. The preclinical discovery, reported Nov....
Bristol, England – The largest review of papers for brain cancer that has spread from the lungs has found abnormalities in the brain cancer and for which licensed drugs could be clinically trialled to find out if they could treat the disease. The research led by the University of Bristol...